This committee develops recommendations for amendment of Board compounding rules or creation of new rules, to clarify standards or to impose requirements to strengthen patient protection and quality of care. This committee also makes recommendations to the full board regarding bills filed with the legislature.
More Latest News
September 23, 2016
On September 20-21, 2016 Allison Dudley, Executive Director and David Flynn, Counsel to the Board attended an inter-governmental working meeting at the Food and Drug Administration to discuss the oversight of drug compounding and the relationship between the activities of … Continue reading
September 9, 2016
The Florida Department of Health, Division of Medical Quality Assurance (MQA) announces the following meetings: Continue reading